Clinical Management of HIV Drug Resistance

Broder, 2010, The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic, Antivir. Res., 85, 1, 10.1016/j.antiviral.2009.10.002

Tsibris, 2010, Antiretroviral therapy in the clinic, J. Virol., 84, 5458, 10.1128/JVI.02524-09

Volberding, 2010, Antiretroviral therapy and management of HIV infection, Lancet, 376, 49, 10.1016/S0140-6736(10)60676-9

Paredes, 2010, Clinical management of HIV-1 resistance, Antivir. Res., 85, 245, 10.1016/j.antiviral.2009.09.015

Hogg, R.S., Bangsberg, D.R., Lima, V.D., Alexander, C., Bonner, S., Yip, B., Wood, E., Dong, W.W., Montaner, J.S., and Harrigan, P.R. (2006). Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med., 3.

Little, 2008, Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection, J. Virol., 82, 5510, 10.1128/JVI.02579-07

Vo, 2008, Durability and outcome of initial antiretroviral treatments received during 2000–2005 by patients in the Swiss HIV Cohort Study, J. Infect. Dis., 197, 1685, 10.1086/588141

Huang, 2008, The prevalence of transmitted antiretroviral drug resistance in treatment-naive patients and factors influencing first-line treatment regimen selection, HIV Med., 9, 285, 10.1111/j.1468-1293.2008.00561.x

Perelson, 1996, HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time, Science, 271, 1582, 10.1126/science.271.5255.1582

Bonhoeffer, 1997, Human immunodeficiency virus drug therapy and virus load, J. Virol., 71, 3275, 10.1128/jvi.71.4.3275-3278.1997

Coffin, 1996, HIV viral dynamics, AIDS, 10, S75

Frost, 2000, Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: The relative roles of drift and selection, J. Virol., 74, 6262, 10.1128/JVI.74.14.6262-6268.2000

Johnson, 2005, Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated, J. Infect. Dis., 192, 16, 10.1086/430741

Palmer, 2006, Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy, AIDS, 20, 701, 10.1097/01.aids.0000216370.69066.7f

Hu, 2003, Retroviral recombination: Review of genetic analyses, Front. Biosci., 8, d143, 10.2741/940

Barry, 1997, Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations, Clin. Pharmacokinet., 32, 194, 10.2165/00003088-199732030-00003

Preston, 2003, Pharmacodynamics and clinical use of anti-HIV drugs, Infect. Dis. Clin. North Am., 17, 651, 10.1016/S0891-5520(03)00064-3

Demeter, 2009, A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients, AIDS, 23, 357, 10.1097/QAD.0b013e32831f9148

Kredo, T., Van der Walt, J.S., Siegfried, N., and Cohen, K. (2009). Therapeutic drug monitoring of antiretrovirals for people with HIV. Cochrane Database Syst. Rev., CD007268.

Simoni, 2008, Strategies for promoting adherence to antiretroviral therapy: a review of the literature, Curr. Infect. Dis. Rep., 10, 515, 10.1007/s11908-008-0083-y

Simoni, 2010, Antiretroviral adherence interventions: Translating research findings to the real world clinic, Curr. HIV/AIDS Rep., 7, 44, 10.1007/s11904-009-0037-5

Hart, 2010, Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review, J. Acquir. Immune Defic. Syndr., 54, 167, 10.1097/QAI.0b013e3181d9a330

Viechtbauer, 2010, Standard care impact on effects of highly active antiretroviral therapy adherence interventions: A meta-analysis of randomized controlled trials, Arch. Intern. Med., 170, 240, 10.1001/archinternmed.2009.536

Rosenblum, M., Deeks, S.G., van der Laan, M., and Bangsberg, D.R. (2009). The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS ONE, 4.

Bello, 2007, Plasma viral load threshold for sustaining intrahost HIV type 1 evolution, AIDS Res. Hum. Retroviruses, 23, 1242, 10.1089/aid.2007.0074

Persaud, 2000, A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children, J. Clin. Invest., 105, 995, 10.1172/JCI9006

DePasquale, 2000, Antiretroviral resistance during successful therapy of HIV type 1 infection, Proc. Natl. Acad. Sci. U. S. A., 97, 10948, 10.1073/pnas.97.20.10948

Shen, 2008, Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection, J. Allergy Clin. Immunol., 122, 22, 10.1016/j.jaci.2008.05.033

Maldarelli, 2011, Targeting viral reservoirs: Ability of antiretroviral therapy to stop viral replication, Curr. Opin. HIV AIDS, 6, 49, 10.1097/COH.0b013e32834134ea

Buzon, 2010, HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects, Nat. Med., 16, 460, 10.1038/nm.2111

Lakhman, 2009, Pharmacogenomics of CYP3A: Considerations for HIV treatment, Pharmacogenomics, 10, 1323, 10.2217/pgs.09.53

Aihara, 2011, Pharmacogenetics of cutaneous adverse drug reactions, J. Dermatol., 38, 246, 10.1111/j.1346-8138.2010.01196.x

Grant, 2003, Accuracy of the TRUGENE HIV-1 genotyping kit, J. Clin. Microbiol., 41, 1586, 10.1128/JCM.41.4.1586-1593.2003

Pandit, 2008, HIV-1 drug resistance genotyping quality assessment: results of the ENVA7 Genotyping Proficiency Programme, J. Clin. Virol., 43, 401, 10.1016/j.jcv.2008.08.021

Thompson, 2010, Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel, JAMA, 304, 321, 10.1001/jama.2010.1004

Labayru, 2005, RNA extraction prior to HIV-1 resistance detection using Line Probe Assay (LiPA): comparison of three methods, J. Clin. Virol., 32, 265, 10.1016/j.jcv.2004.08.007

Lalonde, 2007, Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies, J. Clin. Microbiol., 45, 2604, 10.1128/JCM.00431-07

Re, M.C., Monari, P., Bon, I., Gibellini, D., Vitone, F., Borderi, M., and La Placa, M. (2001). Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. BMC Microbiol., 1.

Adachi, 1986, Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone, J. Virol., 59, 284, 10.1128/jvi.59.2.284-291.1986

Fisher, 1985, A molecular clone of HTLV-III with biological activity, Nature, 316, 262, 10.1038/316262a0

Costagliola, 2004, Clinically validated genotype analysis: guiding principles and statistical concerns, Antivir. Ther., 9, 465, 10.1177/135965350400900420

Vercauteren, 2006, Algorithms for the interpretation of HIV-1 genotypic drug resistance information, Antivir. Res., 71, 335, 10.1016/j.antiviral.2006.05.003

(2011, February 21). HIV Drug Resistance Website. Available online: http://hivdb.stanford.edu.

Nidtha, 2001, Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons, Proc. Natl. Acad. Sci. U. S. A., 98, 13907, 10.1073/pnas.241300698

Stephan, 2010, Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R, J. Infect., 61, 346, 10.1016/j.jinf.2010.06.008

Shi, 1997, A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors, Antimicrob. Agents Chemother., 41, 2781, 10.1128/AAC.41.12.2781

Hertogs, 1998, A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs, Antimicrob. Agents Chemother., 42, 269, 10.1128/AAC.42.2.269

Petropoulos, 2000, A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 44, 920, 10.1128/AAC.44.4.920-928.2000

Kellam, 1994, Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates, Antimicrob. Agents Chemother., 38, 23, 10.1128/AAC.38.1.23

Debiaggi, 2002, Distinct mutational drug resistance profiles of HIV-1 RNA in plasma and culture isolates of patients receiving antiretroviral therapy, Intervirology, 45, 52, 10.1159/000050087

Qari, 2002, Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1, J. Clin. Microbiol., 40, 31, 10.1128/JCM.40.1.31-35.2002

Robinson, 2000, HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays, AIDS Res. Hum. Retroviruses, 16, 1149, 10.1089/088922200414992

Nalivaika, 2004, Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease, J. Virol., 78, 12446, 10.1128/JVI.78.22.12446-12454.2004

Kolli, 2009, Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance, J. Virol., 83, 11027, 10.1128/JVI.00628-09

Swanstrom, 2004, Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects, J. Infect. Dis., 190, 886, 10.1086/422692

Harrigan, 2001, World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing, AIDS, 15, 1671, 10.1097/00002030-200109070-00010

Winters, 2008, Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data, J. Acquir. Immune Defic. Syndr., 48, 26, 10.1097/QAI.0b013e31816d9bf4

Mazzotta, 2003, Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial, J. Acquir. Immune Defic. Syndr., 32, 268, 10.1097/00126334-200303010-00005

Saracino, 2004, Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open-label, randomized, multicenter study (PhenGen), J. Acquir. Immune Defic. Syndr., 37, 1587, 10.1097/00126334-200412150-00011

Torti, 2005, A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study, Clin. Infect. Dis., 40, 1828, 10.1086/429917

Beerenwinkel, 2003, Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes, Nucleic. Acids Res., 31, 3850, 10.1093/nar/gkg575

(2023, February 21). geno2pheno 3.2. Available online: www.geno2pheno.org.

(2023, February 21). HIV French Resistance Website. Available online: http://www.hivfrenchresistance.org.

(2011, February 21). REGA. Available online: http://regaweb.med.kuleuven.be/software/rega_algorithm/.

Altmann, 2009, Advantages of predicted phenotypes and statistical learning models in inferring virological response to antiretroviral therapy from HIV genotype, Antivir. Ther., 14, 273, 10.1177/135965350901400201

Liu, 2006, Web resources for HIV type 1 genotypic-resistance test interpretation, Clin. Infect. Dis., 42, 1608, 10.1086/503914

(2023, February 21). IASUSA. Available online: http://www.iasusa.org/resistance_mutations/index.html.

Zeichner, S., and Read, J. (2006). Handbook of Pediatric HIV Care, Cambridge University Press.

Hales, G., Birch, C., Crowe, S., Workman, C., Hoy, J.F., Law, M.G., Kelleher, A.D., Lincoln, D., and Emery, S. (2006). A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS Clin. Trials, 1.

Hsu, 2003, Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients, Antimicrob. Agents Chemother., 47, 350, 10.1128/AAC.47.1.350-359.2003

Marcelin, 2005, Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients, Antimicrob. Agents Chemother., 49, 1720, 10.1128/AAC.49.5.1720-1726.2005

Shen, 2008, Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs, Nat. Med., 14, 762, 10.1038/nm1777

Henrich, 2010, Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy, Clin. Infect. Dis., 51, 93, 10.1086/653430

Durant, 1999, Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial, Lancet, 353, 2195, 10.1016/S0140-6736(98)12291-2

Cohen, 2002, A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy, AIDS, 16, 579, 10.1097/00002030-200203080-00009

Cingolani, 2002, Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: A randomized study (ARGENTA), AIDS, 16, 369, 10.1097/00002030-200202150-00008

Meynard, 2002, Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial, AIDS, 16, 727, 10.1097/00002030-200203290-00008

Tural, 2002, Clinical utility of HIV-1 genotyping and expert advice: the Havana trial, AIDS, 16, 209, 10.1097/00002030-200201250-00010

Durant, 2000, Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt Study, AIDS, 14, 1333, 10.1097/00002030-200007070-00005

Baxter, 2000, A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS, AIDS, 14, F83, 10.1097/00002030-200006160-00001

Zolopa, 2005, Accuracy, precision, and consistency of expert HIV type 1 genotype interpretation: an international comparison (The GUESS Study), Clin. Infect. Dis., 41, 92, 10.1086/430706

Haubrich, 2005, A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575, AIDS, 19, 295

Panidou, 2004, Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis, AIDS, 18, 2153, 10.1097/00002030-200411050-00007

Palella, 2009, The association of HIV susceptibility testing with survival among HIV-infected patients receiving antiretroviral therapy: A cohort study, Ann. Intern. Med., 151, 73, 10.7326/0003-4819-151-2-200907210-00003

(2009). Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. .

Gazzard, 2008, British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008, HIV Med., 9, 563, 10.1111/j.1468-1293.2008.00636.x

Sarafianos, 2009, Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition, J. Mol. Biol., 385, 693, 10.1016/j.jmb.2008.10.071

Sarafianos, 1999, Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids, Proc. Natl. Acad. Sci. U. S. A., 96, 10027, 10.1073/pnas.96.18.10027

Gotte, 2007, Mechanisms of resistance associated with excision of incorporated nucleotide analogue inhibitors of HIV-1 reverse transcriptase, Curr. Opin. HIV AIDS, 2, 103, 10.1097/COH.0b013e3280287a60

Theys, 2010, Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine, J. Gen. Virol., 91, 1898, 10.1099/vir.0.022657-0

Quan, 2003, Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation, Antimicrob. Agents Chemother., 47, 747, 10.1128/AAC.47.2.747-754.2003

2008, Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase, Virus Res., 134, 124, 10.1016/j.virusres.2007.12.015

Matamoros, 2006, Insertions and deletions in HIV-1 reverse transcriptase: consequences for drug resistance and viral fitness, Curr. Pharm. Des., 12, 1811, 10.2174/138161206776873608

Miller, 2001, Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples, Nucleos. Nucleot. Nucleic Acids, 20, 1025, 10.1081/NCN-100002483

Nikolenko, 2007, Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance, Proc. Natl. Acad. Sci. U. S. A., 104, 317, 10.1073/pnas.0609642104

Brehm, 2007, Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine, J. Virol., 81, 7852, 10.1128/JVI.02203-06

Nikolenko, 2007, Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance, J. Virol., 81, 6837, 10.1128/JVI.02820-06

Ren, 2008, Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase, Virus Res., 134, 157, 10.1016/j.virusres.2007.12.018

Ding, 1998, Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution, J. Mol. Biol., 284, 1095, 10.1006/jmbi.1998.2208

Bernstein, 2000, Recent changes to RasMol, recombining the variants, Trends Biochem. Sci., 25, 453, 10.1016/S0968-0004(00)01606-6

Sayle, 1995, RASMOL: Biomolecular graphics for all, Trends Biochem. Sci., 20, 374, 10.1016/S0968-0004(00)89080-5

Delgado, 2005, NNRTI hypersusceptibility, AIDS Read., 15, 24

Haubrich, 2007, Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359, HIV Clin. Trials, 8, 63, 10.1310/hct0802-63

Shulman, 2005, Nonnucleoside reverse transcriptase inhibitor phenotypic hypersusceptibility can be demonstrated in different assays, J. Acquir. Immune Defic. Syndr., 39, 78, 10.1097/01.qai.0000159517.78100.7b

Ambrose, 2009, The human immunodeficiency virus type 1 nonnucleoside reverse transcriptase inhibitor resistance mutation I132M confers hypersensitivity to nucleoside analogs, J. Virol., 83, 3826, 10.1128/JVI.01968-08

Clark, 2006, Reverse transcriptase mutations 118I, 208Y, and 215Y cause HIV-1 hypersusceptibility to non-nucleoside reverse transcriptase inhibitors, AIDS, 20, 981, 10.1097/01.aids.0000222069.14878.44

Demeter, 2008, Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience, HIV Clin. Trials, 9, 11, 10.1310/hct0901-11

Anderson, J., Schiffer, C., Lee, S.K., and Swanstrom, R. (2009). Viral protease inhibitors. Handb. Exp. Pharmacol., 85–110.

Lefebvre, 2008, Resilience to resistance of HIV-1 protease inhibitors: Profile of darunavir, AIDS Rev., 10, 131

Nalam, 2008, New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitors, Curr. Opin. HIV AIDS, 3, 642, 10.1097/COH.0b013e3283136cee

Shafer, 2008, HIV-1 drug resistance mutations: an updated framework for the second decade of HAART, AIDS Rev., 10, 67

Turner, 2004, The influence of protease inhibitor resistance profiles on selection of HIV therapy in treatment-naive patients, Antivir. Ther., 9, 301, 10.1177/135965350400900308

Mathias, 2010, Pharmacokinetics and pharmacodynamics of GS-9350: A novel pharmacokinetic enhancer without anti-HIV activity, Clin. Pharmacol. Ther., 87, 322, 10.1038/clpt.2009.228

Nalivaika, 2002, Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes, Structure, 10, 369, 10.1016/S0969-2126(02)00720-7

Whitcomb, 2007, Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism, Antimicrob. Agents Chemother., 51, 566, 10.1128/AAC.00853-06

Lalezari, 2003, Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America, N. Engl. J. Med., 348, 2175, 10.1056/NEJMoa035026

Lazzarin, 2003, Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia, N. Engl. J. Med., 348, 2186, 10.1056/NEJMoa035211

Melby, 2006, Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2, AIDS Res. Hum. Retroviruses, 22, 375, 10.1089/aid.2006.22.375

Poveda, 2004, Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure, J. Med. Virol., 74, 21, 10.1002/jmv.20141

Deeks, 2007, Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen, J. Infect. Dis., 195, 387, 10.1086/510531

Hazuda, 2004, Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques, Science, 305, 528, 10.1126/science.1098632

Steigbigel, 2008, Raltegravir with optimized background therapy for resistant HIV-1 infection, N. Engl. J. Med., 359, 339, 10.1056/NEJMoa0708975

Zahm, 2008, Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance, Antimicrob. Agents Chemother., 52, 3358, 10.1128/AAC.00271-08

Grant, 2008, Integrase inhibitors: A clinical review of raltegravir and elvitegravir, J. HIV Ther., 13, 36

Hatano, 2010, Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy, J. Acquir. Immune Defic. Syndr., 54, 389, 10.1097/QAI.0b013e3181c42ea4

Schafer, 2010, Integrase inhibitors: A novel class of antiretroviral agents, Ann. Pharmacother., 44, 145, 10.1345/aph.1M309

Clotet, 2010, K.; Lalezari, J.; Young, B.; Huang, J.; Underwood, M.R.; Ait-Khaled, M.; Nichols, W.G. HIV integrase resistance profiles and S/GSK1349572 baseline phenotypic susceptibility for individuals experiencing virological failure on raltegravir and enrolling in the VIKING phase IIb Pilot study (ING112961), Antivir. Ther., 15, A:61

Hare, 2010, Retroviral intasome assembly and inhibition of DNA strand transfer, Nature, 464, 232, 10.1038/nature08784

Brenner, 2007, Resistance and viral subtypes: How important are the differences and why do they occur?, Curr. Opin. HIV AIDS, 2, 94, 10.1097/COH.0b013e32801682e2

Klein, 2008, Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: A systematic review of virologic and biochemical evidence, AIDS Rev., 10, 212

Bandaranayake, 2010, The Effect of Clade Specific Sequence Polymorphisms on HIV-1 Protease Activity and Inhibitor Resistance Pathways, J. Virol., 84, 9995, 10.1128/JVI.00505-10

Brenner, 2003, A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors, AIDS, 17, F1, 10.1097/00002030-200301030-00001

Loemba, 2002, Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT, Antimicrob. Agents Chemother., 46, 2087, 10.1128/AAC.46.7.2087-2094.2002

Champenois, 2008, Expected response to protease inhibitors of HIV-1 non-B subtype viruses according to resistance algorithms, AIDS, 22, 1087, 10.1097/QAD.0b013e3282ff629b

Ciccozzi, 2007, gp41 sequence variability in HIV type 1 non-B subtypes infected patients undergoing enfuvirtide pressure, AIDS Res. Hum. Retroviruses, 23, 1296, 10.1089/aid.2007.0095

Geretti, 2009, Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy, Clin. Infect. Dis., 48, 1296, 10.1086/598502

Holguin, 2007, Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide, J. Clin. Virol., 38, 176, 10.1016/j.jcv.2006.09.002

Pai, 2009, Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996–2008), J. Int. AIDS Soc., 12, 11, 10.1186/1758-2652-12-11

Maiga, 2010, Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naive patients infected with non-B HIV-1 subtypes, Antimicrob. Agents Chemother., 54, 728, 10.1128/AAC.01335-09

Garrido, 2010, Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection, J. Antimicrob. Chemother., 65, 320, 10.1093/jac/dkp423

Gottlieb, 2009, Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: Implications for HIV-2 treatment in resouce-limited West Africa, Clin. Infect. Dis., 48, 476, 10.1086/596504

Ntemgwa, 2009, Antiretroviral drug resistance in human immunodeficiency virus type 2, Antimicrob. Agents Chemother., 53, 3611, 10.1128/AAC.00154-09

Nettles, 2005, Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART, JAMA, 293, 817, 10.1001/jama.293.7.817

Lima, 2009, Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay, J. Acquir. Immune Defic. Syndr., 51, 3, 10.1097/QAI.0b013e31819e721b

Smit, 2009, Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay, J. Acquir. Immune Defic. Syndr., 51, 364, 10.1097/QAI.0b013e3181aa13b3

Yao, 2008, Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays, J. Clin. Microbiol., 46, 834, 10.1128/JCM.02144-07

Manavi, 2008, The significance of low-level plasma HIV viral load on COBAS TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5, HIV Clin. Trials, 9, 283, 10.1310/hct0904-283

Parikh, 2007, Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase, AIDS, 21, 1405, 10.1097/QAD.0b013e3281ac229b

(2011, February 21). AIDSINFO. Available online: http://www.aidsinfo.nih.gov/.

Dykes, 2004, Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine, J. Infect. Dis., 189, 1091, 10.1086/382033

Johnson, J.A., Li, J.F., Wei, X., Lipscomb, J., Bennett, D., Brant, A., Cong, M.E., Spira, T., Shafer, R.W., and Heneine, W. (2007). Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS ONE, 2.

Palmer, 2006, Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission, Proc. Natl. Acad. Sci. U. S. A., 103, 7094, 10.1073/pnas.0602033103

Palmer, 2005, Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis, J. Clin. Microbiol., 43, 406, 10.1128/JCM.43.1.406-413.2005

Coffin, 1995, HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy, Science, 267, 483, 10.1126/science.7824947

Johnson, 2010, Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution, J. Antimicrob. Chemother., 65, 1322, 10.1093/jac/dkq139

Geretti, 2009, Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy, J. Acquir. Immune Defic. Syndr., 52, 569, 10.1097/QAI.0b013e3181ba11e8

Johnson, J.A., Li, J.F., Wei, X., Lipscomb, J., Irlbeck, D., Craig, C., Smith, A., Bennett, D.E., Monsour, M., Sandstrom, P., Lanier, E.R., and Heneine, W. (2008). Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med., 5.

Paredes, 2010, Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure, J. Infect. Dis., 201, 662

Arribas, 2010, The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/mL., AIDS, 24, 223, 10.1097/QAD.0b013e3283348944

Boltz, V., Lockman, Y.Z.S, Hong, F., Halvas, E., McIntyre, J., Currier, J., Hughes, M., Coffin, J., and Mellors, J. (2010, January 16–19). ; A5208 OCTANE Study Team. NNRTI-resistant Variants Detected by Allele-specific PCR Predict Outcome of NVP-containing ART in Women with Prior Exposure to sdNVP: Results from the OCTANE/A5208 Study. In Proceedings of the Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA.

Hedskog, C., Mild, M., Jernberg, J., Sherwood, E., Bratt, G., Leitner, T., Lundeberg, J., Andersson, B., and Albert, J. (2010). Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing. PLoS ONE, 5.

Lataillade, M., Chiarella, J., Yang, R., Schnittman, S., Wirtz, V., Uy, J., Seekins, D., Krystal, M., Mancini, M., McGrath, D., Simen, B., Egholm, M., and Kozal, M. (2010). Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS ONE, 5.

Le, T., Chiarella, J., Simen, B.B., Hanczaruk, B., Egholm, M., Landry, M.L., Dieckhaus, K., Rosen, M.I., and Kozal, M.J. (2009). Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS ONE, 4.

Mitsuya, 2008, Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations, J. Virol., 82, 10747, 10.1128/JVI.01827-07

Archer, 2009, Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing, AIDS, 23, 1209, 10.1097/QAD.0b013e32832b4399

Martinez, 2008, HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: A view from the clinic and ex vivo, Virus Res, 134, 104, 10.1016/j.virusres.2007.12.021

Hu, 2006, Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1, J. Virol., 80, 7020, 10.1128/JVI.02747-05

Hu, 2007, Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase, J. Acquir. Immune Defic. Syndr., 45, 494, 10.1097/QAI.0b013e31806ada48

Hu, 2010, Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness, J. Acquir. Immune Defic. Syndr., 55, 148, 10.1097/QAI.0b013e3181e9a87a

Lu, 2004, Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20), J. Virol., 78, 4628, 10.1128/JVI.78.9.4628-4637.2004

Paredes, 2009, In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine, J. Virol., 83, 2038, 10.1128/JVI.02154-08

Barbour, 2004, Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection, J. Infect. Dis., 190, 251, 10.1086/422036

Fransen, 2009, Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure, Antimicrob. Agents Chemother., 53, 4522, 10.1128/AAC.00651-09

Picchio, 2000, Altered viral fitness of HIV-1 following failure of protease inhibitor-based therapy, J. Acquir. Immune Defic. Syndr., 25, 289, 10.1097/00126334-200012010-00001

Huang, 2010, Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors, Biom J., 52, 470, 10.1002/bimj.200900173

Prosperi, 2009, Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment, Antivir. Ther., 14, 433, 10.1177/135965350901400315

Revell, 2010, Modelling response to HIV therapy without a genotype: an argument for viral load monitoring in resource-limited settings, J. Antimicrob. Chemother., 65, 605, 10.1093/jac/dkq032

Swindells, 2006, Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression, JAMA, 296, 806, 10.1001/jama.296.7.806

Wilkin, 2009, Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes, J. Infect. Dis., 199, 866, 10.1086/597119